Taros obtains French CIR accreditation until 2020
Taros obtains French CIR accreditation that allow eligible clients to receive 30% of their R&D costs in tax credits
Dortmund, 25.08.2018 ++++
Taros Chemicals, a privately owned CRO focused on serving the needs of pharmaceutical, chemical, agrochemical and biotech companies, announced today that it again obtained its CIR accreditation from French Authorities that allow eligible clients to benefit from tax credits until 2020.
“We are extremely pleased that our customers running R&D operations in France will from now on be able to benefit from the CIR accreditation and the opportunity to save 30% of their incurred R&D costs with projects placed with Taros” said Youri R. Mesmoudi, Executive Vice President.”
Taros’ customers can access a vast array of professional services covering (metal)organic synthesis, medicinal chemistry, drug discovery, process development, scale-up and manufacturing services taking advantage of Taros’ more than 140 years of combined expertise.
About Taros Chemicals
Taros is a privately owned discovery chemistry company, working with global pharmaceutical, biotech and chemical companies since 1999. Alongside our performance chemicals and material science division, Taros’ drug discovery mission is to create drug candidates as potential new medicines. Taros has a strong scientific track record on many biomolecular targets in all main therapeutic areas and thereby adding considerable value to collaborations from target validation and hit identification to lead generation and optimization. Taros’ core expertise ranges from custom synthesis and process development to modern medicinal and computational chemistry, as well as compound library design and production.
Taros was heading the chemistry efforts of the EUR 196 million funded European Lead Factory (2013-2018) and is currently heading its EUR 36.5 million funded continuation (2019-2022). Moreover, Taros is deeply engaged in other research alliances like the EUR 11 million funded Drug Discovery Hub Dortmund.
Press Contact:
Youri R. Mesmoudi, Executive Vice President, e-mail: innovation |at| taros.de
Drug Discovery
Taros’ international and multidisciplinary team has more than 180 years of pharmaceutical R&D experience. Collectively as a team, we worked on more than 120 biomolecular…
Material Science
We create performance chemicals to enhance new materials, plastics, coatings, dyes & inks, cosmetics, flavors and many more research and industrial applications…
